efficacy-bg

Administered in conjunction with an oral antidepressant

SPRAVATO® demonstrated efficacy in adults with TRD and MDSI1

calender

TRD: Short-term study1

Short-term efficacy

direction

TRD: Long-term study1

Long-term efficacy

24-hour

MDSI: Short-term study

Short-term efficacy

SPRAVATO® does not require daily dosing

SPRAVATO® does 
not require daily dosing

SPRAVATO® should be administered in conjunction with an oral antidepressant1

Learn more

janssen carepath

Janssen CarePath

Your one source for Access, Affordability, and Treatment Support for your patients

Learn more

callout-background

Next: What makes SPRAVATO® different?

Learn more

Reference:

1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.